4D Path announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC?? CPUs on Oracle Cloud Infrastructure (OCI), 4D Path's QPOR??
platform--a physics-informed, AI-driven, deterministic software engine--can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost. By running natively on CPUs, QPOR achieves reproducibility, cost efficiency, and scalability at trial level. Clinicians, CROs, and sponsors benefit from explainable, regulatory-friendly insights, enabling faster clinical trial execution and more personalized cancer care.
Validated in blinded retrospective studies and now part of ongoing prospective clinical trials, QPOR demonstrates readiness for real-world oncology applications. QPOR is an end-to-end automated solution--from whole-slide image ingestion to biomarker output--enabling consistent, scalable deployment across clinical sites. Together, AMD, Oracle, and 4D Path are redefining the role of CPUs in powering next-generation AI for clinical trials and precision oncology.
